title: Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis.
abstract: Mild cognitive impairment (MCI) is a condition with an increased risk of developing Alzheimer's disease. Chief complaint and diagnostic criterion in subjects with mild cognitive impairment is memory failure. We hypothesized that cholinergic malfunction may underlie memory impairment in these subjects and applied a low dosage of an acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptors, galantamine (4 mg bid), for 7 days. We used neuropsychological tests to investigate attention, cognitive flexibility, verbal and visual short-term and working memory, susceptibility to interference and episodic memory and functional magnetic resonance imaging to assess spatial navigation both prior to and after treatment. Late episodic learning and delayed recall improved on treatment as did recruitment of the hippocampal region during spatial navigation. Performance in all other neuropsychological measures remained unchanged. We show that an increase of cholinergic neurotransmission in subjects with MCI specifically improves hippocampal function and thus that a cholinergic deficit is functionally relevant in subjects with MCI. Malfunction of the cholinergic system may be tackled pharmacologically via the inhibition of acetylcholinesterase even when the impairment is slight.
authors.affiliation: Memory Clinic, Department of Neurology, University of Ulm, Steinhoevelstr. 1, 89075 Ulm, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Grön
authors.forename: I
authors.initials: I
authors.lastname: Brandenburg
authors.forename: A P
authors.initials: AP
authors.lastname: Wunderlich
authors.forename: M W
authors.initials: MW
authors.lastname: Riepe
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000368:Aged; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D005702:Galantamine / Q000008:administration & dosage*; D006624:Hippocampus / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D008568:Memory / Q000187:drug effects; D009433:Neural Inhibition / Q000187:drug effects*; D020127:Recovery of Function / Q000187:drug effects; D012720:Severity of Illness Index; D009435:Synaptic Transmission / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D005702:Galantamine; D000109:Acetylcholine